logo
Plus   Neg
Share
Email

Roche: Updated Data Confirms Tecentriq With Avastin Substantially Improves Overall Survival In HCC

Roche (RHHBY) said it will present updated overall survival data from the phase III IMbrave150 study evaluating Tecentriq in combination with Avastin, compared with sorafenib, in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy. After a median follow-up of 15.6 months, the updated analysis showed that Tecentriq in combination with Avastin reduced the risk of death by 34%, with a median overall survival of 19.2 months, compared with 13.4 months for sorafenib.

The company said the updated overall survival, along with progression free survival and objective response rate results, were consistent with the primary analysis and support the use of the combination in HCC.

"These results show that Tecentriq in combination with Avastin provides the longest survival that we've ever seen in a front-line phase III study in unresectable hepatocellular carcinoma," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Netflix Inc. (NFLX) - Shares of the video streaming giant jumped 12% after it reported fourth-quarter results and strong subscriber additions. Netflix added 8.51 million subscribers globally in the quarter, far ahead of its forecast of 6.00 million, to end the quarter with 203.66 million subscribers.... Best Buy said it is partnering Popsockets to bring products designed by teens from the company's community programs to its store shelves. The electronics retailer will sell the teen-designed PopGrips in its stores as part of its "Black History Month" campaign. The campaign is intended to celebrate and encourage young artists. Goldman Sachs Group Inc. (GS) on Tuesday reported a fourth-quarter profit that more than doubled from last year, reflecting a surge in investment banking revenues and lower provisions for bad loans. Net revenues for the quarter rose 18 percent. Both quarterly earnings per share and revenues topped analysts' expectations.
Follow RTT